PillRx only · Capsule · Oral
Imipramine Pamoate
Imipramine Pamoate
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US8 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$3.167
Latest avg · Jul 22, 2026
-2%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.3K
Rx · 2026 Q1
53K
Units dispensed
-9%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | unknown | 4 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | unknown | 4 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Oct 8, 2021RECALLRecall (Class II): Imipramine Pamoate Capsules 125 mg, 30-count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, M…
Out of specification result observed in a dissolution test at the 9-month long term stability time point. — Recalling firm: Lupin Pharmaceuticals Inc. — Distributed Nationwide in the USA.